A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 doses

Blood Adv. 2022 Apr 12;6(7):2247-2249. doi: 10.1182/bloodadvances.2021006599.

Authors

Affiliations

¹ Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, and.
² Department of Medical Biotechnologies, University of Siena, Siena, Italy; and.
³ Department of Medical Sciences, Infectious and Tropical Diseases Unit, and.
⁴ Cellular Therapy Unit, Department of Innovation, Experimentation, Clinical and Translational Research, University Hospital of Siena, Siena, Italy.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

2019-nCoV Vaccine mRNA-1273
Antibodies, Viral
Antibody Formation
COVID-19* / prevention & control
Humans
SARS-CoV-2*

Substances

Antibodies, Viral
2019-nCoV Vaccine mRNA-1273